pharmaceuticals
publication date
Revenue Cycle
Is HHS Reviving its Plans for a 340B Rebate Model?
While a federal judge squashed earlier plans for a 340B rebate pilot program, HHS appears poised to relaunch its attempts...
Revenue Cycle
Federal Court Blocks Implementation of 340B Rebate Pilot
A federal court has blocked the implementation of the 340B rebate pilot, sparing safety-net hospitals from potential cash-flow crises and...
CMO
Older Americans Quit Weight-Loss Drugs in Droves
A JAMA Cardiology study found that among Americans 65 and up with diabetes, about 60% discontinued semaglutide within a year.
Revenue Cycle
Infographic: Quick Guide to the 340B Rebate Model Pilot Program
As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the...
Revenue Cycle
Providers Sue to Stop 340B Rebate Pilot
The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs,...
Revenue Cycle
Infographic: 3 Expert Quotes on 340B Reform
Three expert witnesses at a recent Senate HELP Committee hearing outlined weaknesses and misaligned incentives driving growth in the 340B...
Revenue Cycle
GAO, CBO Testimonies Call for 340B Reform
Testimony from the GAO and CBO at a recent Senate hearing called for 340B reform, citing misaligned incentives due to...
Revenue Cycle
Making the Case for 340B Reforms
Ryan Long, the co-author of a recent USC Schaeffer Center white paper on the 340B Drug Pricing Program, argues that...
CMO
Trump Claims 'No Downside' to Avoiding Tylenol During Pregnancy. He's Wrong.
Trump's advice has no clear basis in research and contradicts long-standing science and medical guidance.
CMO
Why Are More Older People Dying After Falls?
In 2023, the most recent year of data from the CDC, more than 41,000 Americans over 65 died from falls.
Revenue Cycle
AHA Asks DOJ, FTC to Probe Drugmakers for Anticompetitive 340B Tactics
The American Hospital Association says that the timing of drug companies' proposed 340B rebate model suggests a collective effort to...
Payer
As Insurers Struggle with GLP-1 Drug Costs, Some Seek to Wean Patients Off
Research suggests GLP-1s must be used indefinitely to maintain weight loss and related health benefits.